1387PDifferences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)
Hernando Cubero, J, Grande, E, Castellano Gauna, D, Ibrahim, T, Fazio, N, Lopez, C, Teulé, A, Valle, J W, Alonso, V, Molina-Cerrillo, J, Tafuto, S, Custodio, A, Trejo, L, Casteras, A, Manneh Kopp, R,Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz256.007
Date:
October, 2019
File:
PDF, 77 KB
2019
File converter
More search results
More benefits 
